US2012129954A1PendingUtilityA1

Carboxymethylcellulose polyethylene glycol compositions for medical uses

53
Individually held — no corporate assignee on recordPriority: Nov 28, 2007Filed: Oct 3, 2011Published: May 24, 2012
Est. expiryNov 28, 2027(~1.4 yrs left)· nominal 20-yr term from priority
Inventors:Samuel J. FalconeRichard A. Berg
A61P 41/00A61L 31/042A61F 2002/30224A61L 2430/38A61F 2230/0071A61F 2002/448A61F 2250/0068C08B 11/20A61L 31/14A61F 2/441Y10T428/2982A61L 2400/06C08J 3/246A61L 31/16A61F 2002/30677A61F 2002/30242A61F 2002/3068A61L 27/50A61L 27/20A61L 27/54A61F 2002/30062A61F 2210/0004A61F 2002/4435A61L 27/58A61L 31/146C08L 1/286A61F 2002/444A61L 31/148A61L 2400/10A61F 2002/30581C08J 2301/08C08J 2471/00A61K 47/60A61L 31/06A61L 2430/02A61P 17/02A61L 27/56
53
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions comprising carboxypolysaccharides (CPS) including carboxymethyl cellulose (CMC) and polyethylene glycols (PEGs) are provided where the PEG is a PEG-epoxide covalently linked to the CPS. In certain embodiments, the PEG attaches to only one CPS, forming a decorated CPS. In other embodiments, bi-functional PEG molecules are attached to adjacent CPSs, thereby forming a covalently cross-linked composition. Additional embodiments include PEG/CMC compositions where the PEG is a multi-branch PEG and/or a multi-arm PEG. PEG/CMC compositions can be made with desired viscoelastic properties, and such compositions can be used as space-filling materials, load-bearing materials, anti-adhesion compositions, drug delivery vehicles or lubrication of tissues and medical instruments.

Claims

exact text as granted — not AI-modified
1 . A biologically compatible implantable PEG/CMC composition, comprising:
 a carboxymethyl cellulose (CMC); and   a polyethylene glycol (PEG) having at least two epoxide moieties, said PEG linked to said CMC via an addition reaction of an epoxide moiety to a carboxyl or an alcohol moiety of said CMC forming a cross-linked PEG/CMC gel soluble in physiologically compatible aqueous medium having a carboxymethyl anhydroglucose unit (CMAG) to epoxide (EP) ratio of between about 3.6 and 14.3, said gel when in solution having a tan δ of <0.5 throughout the frequency range of about 0.1 rad/sec to about 100 rad/sec.   
     
     
         2 . The biologically compatible implantable PEG/CMC composition of  claim 1 , where said CMC and a PEG are linked by way of an ether linkage. 
     
     
         3 . The biologically compatible implantable PEG/CMC composition of  claim 1 , where said CMC and a PEG are linked by way of an ester linkage. 
     
     
         4 . The biologically compatible implantable PEG/CMC composition of  claim 1 , wherein the ratio of CMC repeat units (CMAG) to epoxide units is in the range of about 0.5 to about 30. 
     
     
         5 . The biologically compatible implantable PEG/CMC composition of  claim 1 , further comprising an aqueous medium. 
     
     
         6 . The biologically compatible implantable PEG/CMC composition of  claim 1 , where said composition comprises a PEG/CMC composition in aqueous suspension. 
     
     
         7 . The biologically compatible implantable PEG/CMC composition of  claim 1 , said PEG/CMC composition being a membrane. 
     
     
         8 . The biologically compatible implantable PEG/CMC composition of  claim 1 , further comprising a drug. 
     
     
         9 . The biologically compatible implantable PEG/CMC composition of  claim 1 , wherein said composition is a bead, solid sphere or sponge. 
     
     
         10 . The biologically compatible implantable PEG/CMC composition of  claim 1 , wherein said PEG/CMC composition is a PEG/CMC particulate in a PEG/CMC aqueous gel. 
     
     
         11 . The biologically compatible implantable PEG/CMC composition of  claim 1 , where said PEG is a multiarm PEG or a multibranched PEG. 
     
     
         12 . A method for manufacturing a PEG/CMC composition, comprising the steps:
 selecting a CMC;   selecting a polyethylene glycol diglycidyl ether (PEGDDE);   mixing said CMC and said PEGDDE in aqueous solution;   forming a cross-linked composition of said PEG linked to said CMC via an addition reaction of an epoxide moiety to a carboxyl or an alcohol moiety of said CMC forming a PEG/CMC gel soluble in physiologically compatible aqueous medium having a carboxymethyl anhydroglucose unit (CMAG) to epoxide (EP) ratio of between about 3.6 and 14.3, said gel when in solution having a tan δ of <0.5 throughout the frequency range of about 0.1 rad/sec to about 100 rad/sec.; and   isolating said PEG/CMC composition, where   
     
     
         13 . The method of  claim 12 , further comprising adding a catalyst is selected from the group consisting of acid catalysts and base catalysts. 
     
     
         14 . The method of  claim 13 , said acidic catalyst being acetic acid or citric acid. 
     
     
         15 . The method of  claim 13 , said base catalyst being sodium hydroxide or ammonium hydroxide. 
     
     
         16 . The method of  claim 13 , said PEG being a multiarm PEG or a multibranched PEG. 
     
     
         17 . The method of  claim 12 , wherein the ratio of CMAG to EP is in the range of about 0.5 to about 30. 
     
     
         18 . A biologically compatible implantable PEG/CMC composition, comprising:
 a carboxymethyl cellulose (CMC); and   a polyethylene glycol (PEG) having at least one epoxide moiety, said PEG linked to said CMC via an addition reaction of an epoxide moiety to a carboxyl or an alcohol moiety of said CMC

Join the waitlist — get patent alerts

Track US2012129954A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.